Author: therawinformant

The Auroch Minerals Ltd (ASX: AOU) share price is surging higher again today, up 8.33% in late afternoon trading after an earlier rise of 11%. This comes after the company announced promising results of a second diamond drill test at its Leinster Nickel Project.

Auroch holds a nickel exploration portfolio with its Nepean, Saints and Leinster projects, all located within the Goldfields region of Western Australia.

Today’s surge sees the Auroch share price trading up at a more than 7-year high to 20 cents per share, up 43% so far in November. Year-to-date Auroch’s share price is up 233%.

By comparison the All Ordinaries Index (ASX: XAO) is down 1.3% so far this year.

What’s driving the Auroch share price up today?

Auroch told the ASX this morning that its second diamond drillhole at the Horn (located in its Leinster Nickel Project) had intersected further massive nickel sulphides. This follows on the thick massive to semi-massive nickel sulphide intersection reported from its first test hole at the Horn.

The company said results from the second drill hole reaffirmed the thickness and continuity of the massive nickel-sulphide mineralisation at a fairly shallow depth. Auroch also pointed to the potential for targeting further mineralisation extensions along the strike to the north of its Horn Prospect.

Commenting on the results, Auroch managing director Aidan Platel said:

The drilling at Horn continues to deliver with another impressive nickeliferous massive sulphide intercept in our second hole. Importantly, the intersection has extended the strike of the known nickel sulphide mineralisation, providing a thick intercept where the mineralisation was previously thought to have pinched out.

The thickness and continuity of the massive nickel sulphide mineralisation at such a shallow depth continues to excite, and we look forward to what the remainder of the diamond program and the pending assays results will bring. We are already looking beyond this current program and planning drilling programs to explore the large strike potential to the north of the Horn Prospect.

More reading

• Look out for the Auscann (ASX:AC8) and Cannpal (ASX:CP1) share prices post trading halt
• Why the Global Health (ASX:GLH) share price is surging up today
• Why the DroneShield (ASX:DRO) share price shot up 10% today
• The Cleanspace (ASX:CSX) share price is soaring 12% higher today. Here’s why.
• Sky Network (ASX:SKT) share price shoots 6% higher on upgraded guidance

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The Auroch (ASX:AOU) share price rocketed 11% higher today. Here’s why. appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3nx64zc

The Primewest Group Ltd (ASX: PWG) share price is up by more than 6% in late afternoon trading.

This follows on the company releasing a takeover announcement for its wholly owned subsidiary, Vitalharvest Freehold Trust (ASX: VTH).

Today’s gains have seen the Primewest share price return to just a 4.2% loss year-to-date. Vitalharvest’s share price is up 28.0% so far in 2020.

By comparison the All Ordinaries Index (ASX: XAO) is down 1.3% since 2 January.

What do Primewest and Vitalharvest do?

Established in 1995, Primewest is an Australian property fund manager. The company has over $4.6 billion of assets under management across Australia and in the United States. Primewest manages retail, industrial, commercial, residential, and agricultural assets.

Vitalharvest owns one of the largest portfolios of berry and citrus farms in Australia. Its assets are located across New South Wales, South Australia and Tasmania and are leased to Costa Group (ASX:CGC).

What did Primewest announce to send its share price up 6% today?

After entering a trading halt yesterday, Primewest announced its support for the Macquarie Infrastructure and Real Assets (MIRA) proposal to acquire all of the issued shares of Vitalharvest for $1.00 per share, by way of a trust scheme.

Failing the approval of the trust scheme by shareholders, MIRA proposes to purchase Vitalharvest’s assets for a cash consideration of $300 million.

At least half of Vitalharvest shareholders that are not affiliated with Primewest need to vote in favour of the transaction. Primewest reported it will receive a fee of $8.0 million once the conditions are satisfied.

Commenting on the proposal, David Schwartz, managing director of Primewest, said:

Primewest’s intention is to support the proposed transaction. Upon acquiring the manager of VTH, Primewest sought to reduce the variability in earnings associated with the current VTH leases. However, there was no certainty that this strategy was achievable in a suitable timeframe whilst the MIRA Proposal provides cash certainty to all investors at a material premium to the price of VTH units. As such, in the absence of a superior proposal, Primewest intends to vote in favour of the MIRA Proposal.

Primewest continues to actively seek opportunities in the agricultural space and believes there is significant demand from investors to invest in the space.

With Vitalharvest shareholders not yet having voted on the proposed transaction, the Primewest share price will be one to watch.

More reading

• Costa (ASX:CGC) share price lower despite appointing new CEO
• Why the Vitalharvest (ASX:VTH) share price is rocketing 23% higher
• Why Fletcher Building, Santos, Vitalharvest, & Webjet shares are storming higher
• 3 small cap ASX shares with large dividends
• Leading brokers name 3 ASX shares to buy today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia owns shares of and has recommended COSTA GRP FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Primewest (ASX:PWG) share price is soaring 6% higher today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/370rgXV

The AFP Pharmaceuticals Ltd (ASX: AFP) share price is on the march today. This comes after the company announced a raft of agreements and the establishment of a new subsidiary in Europe. The AFP Pharmaceuticals share price is up at an intra-day high of 3.2% to $5.14. This compares to the S&P/ASX 200 Index (ASX: XJO) which is fractionally higher at 0.4% to 6,521 points.

What’s driving the AFP Pharmaceuticals share price?

AFT Pharmaceuticals share price is rising today after the company advised it has opened a representative office in Ireland to strengthen its growth profile across Europe. Management said the decision was based on the ongoing demand in the region for its Maxigesic pain relief products.

The company has appointed the managing director of Ireland’s JED Pharma, Eddie Townslie, as local director of AFT Pharmaceuticals in Europe. JED Pharma is a distributor of Maxigesic IV in Ireland. Prior to his current role, Mr Townslie held the position of export director at pharmaceutical group Pinewood Healthcare.

International growth

Furthermore, the company said Maxigesic IV had been submitted for registration to 27 European countries, with 17 so far approved. AFT Pharmaceuticals noted that as registrations increased, so too would the need for the company to provide local support. This will involve further offices to oversee licensees and distributors such as regulatory services.

The company said it received new licensing, distribution and supply agreements for Maxigesic. The new partner signing is for its Maxigesic IV products in Ireland and Thailand, and Maxigesic tablets in Greece, Pakistan, and Ecuador.

According to a report published by DelveInsight, AFT Pharmaceuticals has a huge market opportunity ahead. Market estimates indicate that Maxigesic has the potential to generate sales of more than $80 million in Europe by 2028.

What did management say?

AFT Pharmaceuticals managing director Dr Hartley Atkinson welcomed the progress, saying:

We are also delighted to have secured agreements for Maxigesic IV distribution with Ireland’s Jed Pharmaceuticals for Ireland, along with Alliance Pharma in Thailand. We have concluded licensing agreements with Switzerland’s Acino for Maxigesic oral dose forms in Ecuador and Greek’s market leading Elpen Pharmaceuticals, along with distribution agreements with the Karachi-based Excel Healthcare Laboratories for Pakistan.

Acino distributes Maxigesic tablets in a broad range of countries including the Central American Common Market (CACM), while the relationship with Excel Healthcare Laboratories and Elpen is new.

We are delighted to continue to expand our partners for Maxigesic and Maxigesic IV around the world with the focus now moving to completion of any remaining regulatory actions and following that product launches.

AFP Pharmaceuticals share price summary

The AFP Pharmaceuticals share price has risen more than 65% since COVID-19 impacted in March. Only last week, the company reached an all-time high of $5.25 after trading at $3.10 just over 8 months ago.

More reading

• Why the Primewest (ASX:PWG) share price is soaring 6% higher today
• 2 highly-rated ASX mid cap shares to buy
• The Flight Centre (ASX:FLT) share price is up 46% in November
• Tussle at Kogan (ASX:KGN) over executive compensations
• Australia’s wage growth slows to a crawl

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the AFP Pharmaceuticals (ASX:AFP) share price is marching higher appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/32UZhaH

At the mid cap side of the market there are a good number of options for investors to choose from.

In fact, so many, it can be hard to decide which ones to choose over others.

Two mid cap shares that come highly rated are listed below. Here’s what you need to know about them:

BINGO Industries Ltd (ASX: BIN)

BINGO is one of Australia’s leading waste management companies. It bolstered its offering last year with the game-changing acquisition of rival Dial a Dump Industries. This acquisition has allowed BINGO to be fully vertically integrated from collections to landfill. It also makes it the largest player in building and demolition waste in Sydney and has diversified its operations.

Last month analysts at UBS put a buy rating and $3.00 price target on the company’s shares. While COVID headwinds continue to weigh on its performance, it believes it is well-placed to benefit from several Federal Budget initiatives. The BINGO share price is currently fetching $2.74.

Damstra Holdings Ltd (ASX: DTC)

Damstra is a growing integrated workplace management solutions provider to multiple industry segments. It provides a cloud-based workplace management platform which is used by businesses globally to track, manage, and protect their workers and assets. Among its offering there are products which have become highly sought after in the current environment such as fever detection and mobility tracking. Like BINGO, the company also strengthened its offering with an acquisition recently. It acquired Vault Intelligence, which is a software company offering solutions which combine health, safety, compliance, and risk management.

One broker that is positive on the company’s prospects is Morgan Stanley. It has an overweight rating and $2.00 price target on Damstra’s shares. This compares to the current Damstra share price of $1.68.

More reading

• Why Althea, BWX, Damstra, & GrainCorp shares are charging higher
• Damstra (ASX:DTC) share price storms higher on AGM update
• Wilson Asset Management thinks these 2 small cap ASX shares are a buy
• Why Bingo, Evolution, JB Hi-Fi, & Super Retail shares are dropping lower
• The Bingo (ASX:BIN) share price dips on AGM

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and recommends Damstra Holdings Ltd. The Motley Fool Australia has recommended Damstra Holdings Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 2 highly-rated ASX mid cap shares to buy appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/38OVa3L

The Flight Centre Travel Group Ltd (ASX: FLT) share price has been among the best performers on the S&P/ASX 200 Index (ASX: XJO) in November.

Since the start of the month, the travel agent giant’s shares have risen a sizeable 46%.

This compares to an excellent gain of 10% by the benchmark index.

Why is the Flight Centre share price rocketing higher this month?

The catalyst for the strong Flight Centre share price gain this month has been news of two potentially effective COVID-19 vaccines.

This has sparked hopes that the global travel market could bounce back quicker than expected, which would be great news for Flight Centre. It is currently operating at a loss despite its rampant cost cutting.

What are the vaccines?

The first vaccine is being developed by biotech giant Pfizer and is a mRNA-based vaccine candidate named BNT162b2.

Last week it released the first set of results from a phase 3 COVID-19 vaccine trial.

In the first interim efficacy analysis, the vaccine candidate was found to be more than 90% effective in preventing COVID-19 in participants with no evidence of prior SARS-CoV-2 infection. This was significantly better than expectations.

Pfizer expects to produce up to 50 million vaccine doses globally in 2020 and then up to 1.3 billion doses in 2021.

The second vaccine, mRNA-1273, comes from US biotech Moderna. At the start of this week, it revealed that its Phase 3 study has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of 94.5%.

Moderna expects to have approximately 20 million doses of mRNA-1273 ready to ship in the U.S. by the end of the year. After which, it remains on track to manufacture 500 million to 1 billion doses globally in 2021.

Both vaccine candidates are using mRNA technology. This is a new approach to vaccines that uses genetic material to provoke an immune response.

What now for Flight Centre share price?

Two brokers that appear to have called time on the Flight Centre share price rally are Macquarie and Citi.

Last week they put neutral ratings and $13.50 and $16.00 price targets, respectively, on its shares. This compares to the current Flight Centre share price of $16.45.

More reading

• Why the Webjet (ASX:WEB) share price is up 48% in November
• Flight Centre and Webjet were among the most traded shares on the ASX last week
• Flight Centre (ASX:FLT) share price on watch amid notes offering and debt refinancing
• Vaccine hopes cause ASX 200 to rise on Tuesday
• Why the Sydney Airport (ASX:SYD) share price rocketed 24% higher today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Flight Centre Travel Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post The Flight Centre (ASX:FLT) share price is up 46% in November appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3pDOEmp

A corporate tussle is brewing at e-commerce retailer Kogan.com Ltd (ASX: KGN) over proposed share options to be granted to its senior executives. The Kogan share price lifted to an intraday high of $19.24 but has since retreated to $18.89, down 0.74% at the time of writing.

What’s being disputed

The Kogan board is proposing to grant 3.6 million share options to chief executive Ruslan Kogan, and 2.4 million share options to his chief financial officer, David Shafer. The board says the share options are meant to be an incentive for the two executives to stay at the company for the next three years. Options are a type of derivatives, giving holders the right but not the obligation to buy the underlying shares at a pre-determined ‘exercise price’. 

But Proxy advisers CGI Glass Lewis, acting on behalf of institutional investors in the matters of executive compensation, has said that these options grants are “overly generous”, and encouraged shareholders to vote down the proposal. The advisers also threatened to vote against the re-election of specific directors in future if the company goes ahead with granting the options. 

The main contention is the exercise price of the options, which was set at $5.29 and perceived to be too low, without strict performance targets attached. Kogan said this exercise price was calculated based on the three-month weighted average price of Kogan shares between 1 February and 30 April, when the market was at its lowest levels due to the coronavirus-induced panic. With the Kogan share price currently aroun $19, these share options are practically already in-the-money, giving both executives a windfall of more than $100 million in paper profits.

What the chairman said

Kogan chairman Greg Ridder defended the options grant proposal, saying that Mr Kogan and Mr Shafer “more than deserved it”:

I want to know that Ruslan is there to drive the hardest driving performance, and he is the smartest guy in the room, he is there to drive that value for all of us. We are making sure there are big incentives for a big outcome.

These guys have been working for close to nothing in the four years they have been with the company. In Ruslan’s cohort of comparable companies that the proxy advisers drew in this, he was the lowest-paid executive among 16 entities and yet was the second highest performing of all those entities.

How has the Kogan share price performed in 2020

Kogan, like other technology-based retailers, has had a fantastic year after the pandemic shifted people’s buying habits to online. The Kogan share price started the year at $7.47 before slumping to $3.79 at the height of market panic in March. It has bounced back strongly to trade at $18.89 today. The company commands a market cap of $2 billion.

More reading

• Why ASX tech shares should fly long after this crisis is over
• Dow Jones hits new record highs. Are ASX 200 shares next?
• Why the Openpay (ASX:OPY) share price is up and down today
• Macquarie (ASX:MQG) picks best ASX stocks to buy for 2021 post-COVID recovery
• These ASX shares have been unstoppable in FY 2021

Eddy Sunarto has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Kogan.com ltd. The Motley Fool Australia has recommended Kogan.com ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Tussle at Kogan (ASX:KGN) over executive compensations appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/36FFmxy

The economic fallout from the COVID-19 pandemic isn’t limited to zero-bound interest rates, ballooning government debt, and cratering share prices for ASX travel and leisure shares.

Australia’s unemployment rate has risen too, despite many jobs being spared by the government’s JobKeeper program.

Data from the Australian Bureau of Statistics (ABS) revealed that the unemployment rate in September, the latest month available, increased to 6.9%. Meanwhile the labour participation rate, people who are working or actively seeking work, fell to 64.8%. The underemployment rate – people who are working but would like to work more hours – also increased to 11.4%

And Australians who are working aren’t likely to have seen much, or any, of a pay rise.

The latest ABS Wage Price Index (WPI), released today, indicated the seasonally adjusted WPI rose just 0.1% in the September quarter. That brings the year-to-date growth down to 1.4%.

Addressing the results, Andrew Tomadini, Head of Price Statistics at the ABS said:

The September quarter is generally a quarter of solid wage growth, however, the impacts of the COVID-19 pandemic contributed to a subdued rate of wage growth in September quarter 2020.

Organisations continued to adjust to the economic uncertainty, recording fewer end of financial year wage reviews and delaying enterprise bargaining agreement increases. This led to a significantly reduced number of jobs recording wage rises when compared to previous September quarters.

Additionally, the staggered implementation schedule of the Fair Work Commission annual wage review moved some regular September quarter wage rises to later quarters.

The ABS notes that most of the private sector wage growth can be attributed to companies restoring wages to normal (or near normal) levels after cutting wages in the June quarter.

South Australia, where until this week the coronavirus had been largely held in check, notched up 1.8% in year-to-date wage growth, the highest of any state or territory.

Victoria, which only recently emerged from months of strict lockdowns after successfully suppressing new community transmissions, recorded the lowest wage growth, at 1.2%.

As Tomadini noted:

September quarter 2020 covers the period when COVID-19 restrictions were impacting parts of Victoria but had started to ease across the majority of other states and we can see the impacts of this in the data.

With several highly promising vaccines underway and Australia largely managing to keep the virus in check, we can all hope for a return to higher wage growth next year.

More reading

• 2 ASX shares making all-time highs today
• Why the Superloop (ASX:SLC) share price is surging higher today
• UK’s Doctor Care Anywhere to dial in to ASX telehealth ranks
• ASX stock of the day: Redbubble (ASX:RBL) shares up 5% today
• Top brokers name 3 ASX shares to buy today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Australia’s wage growth slows to a crawl appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/3lHuB49

The S&P/ASX 200 Index (ASX: XJO) has risen more than 0.3% today, following a day of green yesterday as well. In line with this, many individual companies are rising as a result.

Below, we take a closer look at two ASX shares making new all-time highs today.

REA Group Limited (ASX: REA)

REA Group is a multinational digital advertising business specialising in real estate. The company runs realestate.com.au, realcommercial.com.au and flatmates.com.au. Between them, these three websites operate Australia’s top residential, commercial and share property advertising businesses.

In addition to these well-known brands, the company owns an Australian ‘co-working’ space website called spacely.com.au.

Overseas, the company’s Asian operations in the property space are extensive and stretch across Malaysia, Hong Kong, Indonesia, Singapore, China and Thailand. Not only does the REA Group own and operate this large portfolio, but it also owns significant share portfolios in related companies in the United States and India.

The REA Group share price has been strong in 2020, rising more than 34%. In fact, since the March lows, it has made gains of 126%. Today, the intraday REA Group share price reached as high as $143.99, exceeding its previous high of $142.47 to secure a new record this morning.

However, the REA Group share price has since pulled back slightly and is up by 1.15% to $141 per share at the time of writing. 

Only yesterday the REA Group share price dipped lower by 1.31% following its AGM. It seems investors may have a renewed sense of confidence today, pushing the price to new heights.

Chalice Gold Mines Limited (ASX: CHN)

Another ASX share making all-time highs today is Chalice Gold Mines. Chalice Gold Mines operates a mineral exploration company, exploring for gold, copper, cobalt, palladium, and nickel deposits. One of its main properties is the Julimar Nickel-Copper-Platinum group element project located in the Avon Region, Western Australia. Another major project is the Pyramid Hill gold project located in the Bendigo Region, Victoria. 

Chalice Gold shares went for a massive 17%+ run in morning trade after new results released today showed positive discoveries for the company’s Julimar Nickel-Copper-Platinum project. Following a close of $3.30 yesterday, the Chalice Gold share price was driven as high as $3.88 today. Chalice Gold’s previous all-time high was $3.55.

Overall this year, the Chalice Gold Mines share price is up a staggering 1,568%. The company now holds a market cap of over $1 billion.

More reading

• ASX stock of the day: Redbubble (ASX:RBL) shares up 5% today
• Top brokers name 3 ASX shares to buy today
• Why ASX tech shares should fly long after this crisis is over
• Morgan Stanley updates its share price targets for the big 4 banks
• Why Aristocrat Leisure, Chalice Gold, Westpac, & Whitehaven Coal shares are charging higher

Motley Fool contributor Glenn Leese has no position in any of the stocks mentioned. The Motley Fool Australia has recommended REA Group Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post 2 ASX shares making all-time highs today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/2IJPiOm

The Superloop Ltd (ASX: SLC) share price has been a strong performer on Wednesday.

In afternoon trade the independent connectivity services provider’s shares are up over 4% to 98 cents.

Why is the Superloop share price climbing higher?

Investors have been buying Superloop’s shares following the release of an update at its annual general meeting this morning.

At the meeting the company provided investors with a reminder of how it performed in FY 2020 and its performance so far in the new financial year.

In FY 2020, Superloop delivered revenue of $107 million and earnings before interest, tax, depreciation and amortisation (EBITDA) of $13.5 million. The latter meant the company achieved the midpoint of its guidance range despite the challenges presented by COVID-19.

Management advised that this result was underpinned by significant growth in continuing businesses and prudent cost management.

What about FY 2021?

Superloop revealed that it has started FY 2021 in a positive fashion with strong growth in core fibre connectivity and home broadband during the first quarter.

In addition to this, the company spoke very positively about its enterprise opportunity, noting that IDC estimates that the SD WAN market is seeing remarkable growth. IDC expects a compound annual growth rate of nearly 70% and for the market to be worth US$8 billion by 2021.

Management commented: “With a multibillion dollar addressable opportunity, Superloop’s ambition is to become the leading challenger in this market, and we are extremely well positioned to execute this.”

Guidance.

Management expects core fibre sales growth to lead to strong underlying core EBITDA growth in FY 2021.

It also intends to make a ~$3 million investment in new growth initiatives to drive the accelerated monetisation of its existing assets.

As a result, it is forecasting FY 2021 EBITDA of between $18 million and $20 million. This represents a year on year increase of ~41%.

More reading

• UK’s Doctor Care Anywhere to dial in to ASX telehealth ranks
• ASX stock of the day: Redbubble (ASX:RBL) shares up 5% today
• Top brokers name 3 ASX shares to buy today
• Why ASX tech shares should fly long after this crisis is over
• Morgan Stanley updates its share price targets for the big 4 banks

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of SUPERLOOP FPO. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Why the Superloop (ASX:SLC) share price is surging higher today appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/38S1xDf

The UK-based healthtech company Doctor Care Anywhere lodged a prospectus on 30 October to undertake an initial public offering (IPO) in the Australian capital market on 4 December.

The company aims to raise $102 million with an issue price of $0.80 per share. This is upsized from the company’s original plans to raise $75 million.

Doctor Care Anywhere advises that the majority of the funds raised by the IPO will be used to support investments in marketing and engagement functions, investment in new products and building international business development capabilities.

What is Doctor Care Anywhere?

Doctor Care Anywhere is a London-based telehealth company founded by Doctor Bayu Thakar, a qualified medical doctor and a McKinsey alumnus. 

The company’s business model is to recruit its own clinicians to provide patients with virtual GP consultations in the form of video or phone consultations with GPs who are directly employed by Doctor Care Anywhere. It also provides diagnostic referrals and specialist reviews across the key clinical specialties.

The company has grown rapidly since its inception in 2014, providing services to more than 1,500 corporate and SME clients through its major channel relationships.

The digital health market

The global telehealth market was estimated to be $7.30 billion in 2019 and is forecast to reach $20.50 billion in 2024, growing at a compound annual growth rate of 23.10%.

Doctor Care Anywhere currently focuses on the UK private healthcare market but advises it is looking to accelerate its business expansion to capture this growing telehealth market. 

According to its prospectus, Doctor Care Anywhere has chosen to list in Australia because it is a developed market with investors who understand healthtech and are keen to invest in digital healthcare. 

Doctor Care Anywhere chair Jonathan Baines said:

The impact of COVID-19 on all our lives has demonstrated the vital role that technology can and must play in the future of healthcare. We see DOC at the forefront of this revolution and we have a clear and ambitious growth strategy that aims to create real value for investors in the rapidly growing digital health market.

More reading

• ASX stock of the day: Redbubble (ASX:RBL) shares up 5% today
• Top brokers name 3 ASX shares to buy today
• Why ASX tech shares should fly long after this crisis is over
• Morgan Stanley updates its share price targets for the big 4 banks
• Why Aristocrat Leisure, Chalice Gold, Westpac, & Whitehaven Coal shares are charging higher

Motley Fool contributor Miles Wu has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post UK’s Doctor Care Anywhere to dial in to ASX telehealth ranks appeared first on Motley Fool Australia.

from Motley Fool Australia https://ift.tt/32UbZ9P